Skip to main content
Top
Published in: Clinical and Experimental Medicine 3/2019

01-08-2019 | Colorectal Cancer | Original Article

Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing

Authors: Zora Lasabová, Michal Kalman, Veronika Holubeková, Marián Grendár, Ivana Kašubová, Karin Jašek, Sandra Meršaková, Bibiana Malicherová, Denis Baranenko, Mariusz Adamek, Peter Kruzliak, Lukáš Plank

Published in: Clinical and Experimental Medicine | Issue 3/2019

Login to get access

Abstract

The colorectal cancer harbor germline, somatic or epimutations in mismatch repair genes, MUTYH or POLE gene, which lead to the hypermutated and ultramutator phenotypes with increased immune response. The mutations in POLE gene were reported to occur more frequently in early-onset colorectal cancer (EOCRC), and the patients are strong candidates for checkpoint inhibitor therapy. Here, we report mutation analysis within the endonuclease domain of the POLE gene in the cohort of patients with EOCRC in order to identify recurrent or new mutations and evaluate their association with the presence of tumor-infiltrating lymphocytes (TILs) and peritumoral lymphoid reaction. We have shown a significant association between MSI tumors and TILs (p = 0.004). Using sensitive single-tube nested PCR with subsequent Sanger sequencing, we have found in one female patient diagnosed at age 48 with rectal adenocarcinoma with mucinous elements staged pT3pN2pM1 a silent variant within the exon 9 NM_006231.3 c.849 C > T, NP_00622.2 p.Leu283 = recorded in dSNP as rs1232888774 with MAF = 0.00002. In silico prediction, result showed possible involvement into splicing; therefore, this rare variant can be involved into EOCRC pathogenesis. In the time of precise medicine, it is important to develop screening strategies also for less common conditions such as EOCRC allowing to predict tailored therapy for younger patients suffering from CRC that harbor mutations in the POLE gene.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
2.
go back to reference Network Cancer Genome Atlas. Comprehensive molecular characterization of human and rectal cancer. Nature. 2012;18:330–7.CrossRef Network Cancer Genome Atlas. Comprehensive molecular characterization of human and rectal cancer. Nature. 2012;18:330–7.CrossRef
3.
go back to reference Mahasneh A, Al-Shaheri F, Jamal E. Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: current updates. Exp Mol Pathol. 2017;102:475–83.CrossRefPubMed Mahasneh A, Al-Shaheri F, Jamal E. Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: current updates. Exp Mol Pathol. 2017;102:475–83.CrossRefPubMed
4.
go back to reference Pilati C, Shinde J, Alexandrov LB, et al. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. J Pathol. 2017;242:10–5.CrossRefPubMed Pilati C, Shinde J, Alexandrov LB, et al. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. J Pathol. 2017;242:10–5.CrossRefPubMed
5.
go back to reference Cohen R, Sroussi M, Pilati C, Houry S, Laurent-Puig P, André T. Unresectable metastatic colorectal cancer patient cured with cetuxomab-based chemotherapy: a case report with new molecular insights. Gastrointest Oncol. 2018;9:E23–7.CrossRef Cohen R, Sroussi M, Pilati C, Houry S, Laurent-Puig P, André T. Unresectable metastatic colorectal cancer patient cured with cetuxomab-based chemotherapy: a case report with new molecular insights. Gastrointest Oncol. 2018;9:E23–7.CrossRef
6.
go back to reference Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45:136–44.CrossRefPubMed Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45:136–44.CrossRefPubMed
7.
go back to reference Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18:325–32.CrossRefPubMed Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18:325–32.CrossRefPubMed
8.
go back to reference Church DN, Briggs SE, Palles C, Collaborators NSECG, Kaur K, Taylor J, Tomlinson IP, et al. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013;22:2820–8.CrossRefPubMedPubMedCentral Church DN, Briggs SE, Palles C, Collaborators NSECG, Kaur K, Taylor J, Tomlinson IP, et al. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013;22:2820–8.CrossRefPubMedPubMedCentral
9.
go back to reference The Cancer Genome Atlas Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.CrossRef The Cancer Genome Atlas Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.CrossRef
10.
go back to reference Song Z, Cheng G, Xu C, Wang W, Shao Y, Zhang Y. Clinicopathological characteristics of POLE mutation in patients with non-small cell lung cancer. Lung Cancer. 2018;118:57–61.CrossRefPubMed Song Z, Cheng G, Xu C, Wang W, Shao Y, Zhang Y. Clinicopathological characteristics of POLE mutation in patients with non-small cell lung cancer. Lung Cancer. 2018;118:57–61.CrossRefPubMed
11.
go back to reference Rayner E, van Gool IC, Palles C, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer. 2016;16:71–81.CrossRefPubMed Rayner E, van Gool IC, Palles C, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer. 2016;16:71–81.CrossRefPubMed
12.
go back to reference Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1:207–16.CrossRefPubMed Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1:207–16.CrossRefPubMed
14.
go back to reference Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319–23.CrossRefPubMed Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319–23.CrossRefPubMed
16.
go back to reference Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutations. J Natl Canc Netw. 2017;15:142–7.CrossRef Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutations. J Natl Canc Netw. 2017;15:142–7.CrossRef
17.
go back to reference Ahn SM, Ansari AA, Kim J, et al. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. Oncotarget. 2017;7:68638–49. Ahn SM, Ansari AA, Kim J, et al. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. Oncotarget. 2017;7:68638–49.
18.
go back to reference Connell LC, Mota JM, Braghiroli MI, Hoff PM. The rising incidence of younger patients with colorectal cancer: questions about screening, biology, and treatment. Curr Treat Options Oncol. 2017;18:23.CrossRefPubMed Connell LC, Mota JM, Braghiroli MI, Hoff PM. The rising incidence of younger patients with colorectal cancer: questions about screening, biology, and treatment. Curr Treat Options Oncol. 2017;18:23.CrossRefPubMed
19.
go back to reference Schellerer VS, Merkel S, Schumann SC, et al. Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer: CRC in patietns under 50 years of age. Int J Colorectal Dis. 2012;27:71–9.CrossRefPubMed Schellerer VS, Merkel S, Schumann SC, et al. Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer: CRC in patietns under 50 years of age. Int J Colorectal Dis. 2012;27:71–9.CrossRefPubMed
21.
go back to reference Temko D, Van Gool IC, Rayner E, et al. Somatic POLE exonuclease domain mutation are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 2018;245:283–96.CrossRefPubMedPubMedCentral Temko D, Van Gool IC, Rayner E, et al. Somatic POLE exonuclease domain mutation are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 2018;245:283–96.CrossRefPubMedPubMedCentral
22.
go back to reference Kašubová I, Kalman M, Jašek K, et al. Stratification of patients with colorectal cancer without the recorded family history. Oncol Lett. 2019;17:3649–56.PubMedPubMedCentral Kašubová I, Kalman M, Jašek K, et al. Stratification of patients with colorectal cancer without the recorded family history. Oncol Lett. 2019;17:3649–56.PubMedPubMedCentral
23.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009.
24.
go back to reference Edge SB, Byrd SR, Compton CC. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. Edge SB, Byrd SR, Compton CC. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
25.
go back to reference Jenkins MA, Hayashi S, O’Shea AM, et al. Colon Cancer Family Registry. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population—based study. Gastroenterology. 2007;133:48–56.CrossRefPubMed Jenkins MA, Hayashi S, O’Shea AM, et al. Colon Cancer Family Registry. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population—based study. Gastroenterology. 2007;133:48–56.CrossRefPubMed
26.
go back to reference Hyde A, Fontaine D, Stuckless S, et al. A histology-based model for predicting microsatellite instability in colorectal cancers. Am J Surg Pathol. 2010;34:1820–9.CrossRefPubMed Hyde A, Fontaine D, Stuckless S, et al. A histology-based model for predicting microsatellite instability in colorectal cancers. Am J Surg Pathol. 2010;34:1820–9.CrossRefPubMed
27.
go back to reference Malicherova B, Burjanivova T, Grendar M, et al. Droplet digital PCR for detection of BRAF V600E mutation in formalin-fixed, paraffin-embedded melanoma tissues: a comparison with Cobas 4800, Sanger sequencing, and allele-specific PCR. Am J Transl Res. 2018;10:3773–81.PubMedPubMedCentral Malicherova B, Burjanivova T, Grendar M, et al. Droplet digital PCR for detection of BRAF V600E mutation in formalin-fixed, paraffin-embedded melanoma tissues: a comparison with Cobas 4800, Sanger sequencing, and allele-specific PCR. Am J Transl Res. 2018;10:3773–81.PubMedPubMedCentral
28.
go back to reference Jasek K, Buzalkova V, Minarik G, et al. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tunors. Virchows Arch. 2017;470:29–36.CrossRefPubMed Jasek K, Buzalkova V, Minarik G, et al. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tunors. Virchows Arch. 2017;470:29–36.CrossRefPubMed
29.
go back to reference Esteban-Jurado C, Giménez-Zaragoza D, Muñoz J, et al. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget. 2017;8:26732–43.CrossRefPubMedPubMedCentral Esteban-Jurado C, Giménez-Zaragoza D, Muñoz J, et al. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget. 2017;8:26732–43.CrossRefPubMedPubMedCentral
30.
go back to reference Wang C, Gong J, Tu TY, Lee PP, Fakih M. Immune profiling of microsatellite instability-high and polymerase ε (POLE)- mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. J Gastrointest Oncol. 2018;9:404–15.CrossRefPubMedPubMedCentral Wang C, Gong J, Tu TY, Lee PP, Fakih M. Immune profiling of microsatellite instability-high and polymerase ε (POLE)- mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. J Gastrointest Oncol. 2018;9:404–15.CrossRefPubMedPubMedCentral
Metadata
Title
Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing
Authors
Zora Lasabová
Michal Kalman
Veronika Holubeková
Marián Grendár
Ivana Kašubová
Karin Jašek
Sandra Meršaková
Bibiana Malicherová
Denis Baranenko
Mariusz Adamek
Peter Kruzliak
Lukáš Plank
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 3/2019
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-019-00558-7

Other articles of this Issue 3/2019

Clinical and Experimental Medicine 3/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.